Vaccitech’s VTP-300 was Well-Tolerated and Induced T cells against all targeted HBV antigens in both Healthy Volunteers and Patients with Chronic HBV Infection in Interim Analyses

November 12, 2021

Stay up to date

Get the latest on cutting edge developments from our enterprises straight to your inbox